JP2018520091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520091A5 JP2018520091A5 JP2017557287A JP2017557287A JP2018520091A5 JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5 JP 2017557287 A JP2017557287 A JP 2017557287A JP 2017557287 A JP2017557287 A JP 2017557287A JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- activatable antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022910A JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156835P | 2015-05-04 | 2015-05-04 | |
| US62/156,835 | 2015-05-04 | ||
| US201562220805P | 2015-09-18 | 2015-09-18 | |
| US62/220,805 | 2015-09-18 | ||
| PCT/US2016/030785 WO2016179285A1 (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Division JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520091A JP2018520091A (ja) | 2018-07-26 |
| JP2018520091A5 true JP2018520091A5 (enExample) | 2019-06-20 |
| JP7028648B2 JP7028648B2 (ja) | 2022-03-02 |
Family
ID=55967468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557287A Expired - Fee Related JP7028648B2 (ja) | 2015-05-04 | 2016-05-04 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10745481B2 (enExample) |
| EP (2) | EP3708585A1 (enExample) |
| JP (2) | JP7028648B2 (enExample) |
| KR (1) | KR20180010203A (enExample) |
| CN (2) | CN115340607A (enExample) |
| AU (1) | AU2016257929B2 (enExample) |
| BR (1) | BR112017023872A2 (enExample) |
| CA (1) | CA2984948A1 (enExample) |
| DK (1) | DK3292150T3 (enExample) |
| EA (1) | EA201792414A1 (enExample) |
| ES (1) | ES2796698T3 (enExample) |
| HR (1) | HRP20200721T1 (enExample) |
| HU (1) | HUE049866T2 (enExample) |
| IL (2) | IL292798A (enExample) |
| MX (2) | MX388350B (enExample) |
| PL (1) | PL3292150T3 (enExample) |
| PT (1) | PT3292150T (enExample) |
| RS (1) | RS60222B1 (enExample) |
| SG (2) | SG10202110908WA (enExample) |
| WO (1) | WO2016179285A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| KR102488220B1 (ko) | 2013-09-25 | 2023-01-12 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| KR102466591B1 (ko) * | 2014-01-31 | 2022-11-14 | 싸이톰스 테라퓨틱스, 인크. | 마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| SG10202110908WA (en) | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| MX2019005756A (es) | 2016-11-28 | 2019-08-14 | Chugai Pharmaceutical Co Ltd | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| KR20190089034A (ko) | 2016-12-09 | 2019-07-29 | 시애틀 지네틱스, 인크. | 코일드 코일에 의해 차폐된 이가 항체 |
| SG11202000105QA (en) * | 2017-07-14 | 2020-02-27 | Cytomx Therapeutics Inc | Anti-cd166 antibodies and uses thereof |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| BR112020004231A2 (pt) * | 2017-08-30 | 2020-09-08 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| WO2019051102A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| EP3679068A2 (en) * | 2017-09-08 | 2020-07-15 | Maverick Therapeutics, Inc. | CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| EP3719035A4 (en) | 2017-11-28 | 2021-09-01 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JPWO2019230868A1 (ja) | 2018-05-30 | 2021-06-24 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| AU2019370471A1 (en) * | 2018-11-02 | 2021-05-13 | Cytomx Therapeutics, Inc. | Activatable anti-CD166 antibodies and methods of use thereof |
| SG11202105476XA (en) | 2018-12-06 | 2021-06-29 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| EP3911682A4 (en) * | 2019-01-14 | 2023-03-15 | The Regents of the University of California | COMPOSITIONS AND METHODS TO MODULATE CELLULAR INTERNALIZATION |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20220233705A1 (en) * | 2019-02-26 | 2022-07-28 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| KR102212149B1 (ko) * | 2019-03-28 | 2021-02-04 | 부산대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도 |
| HUE065484T2 (hu) | 2019-04-26 | 2024-05-28 | Immunogen Inc | Camptothecin-származékok |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| WO2020236679A1 (en) * | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| JPWO2020246563A1 (enExample) | 2019-06-05 | 2020-12-10 | ||
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| CN114650844A (zh) * | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | 抗cd47抗体、可活化抗cd47抗体及其使用方法 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| CA3174665A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| IL302968A (en) * | 2020-11-16 | 2023-07-01 | Cleveland Clinic Found | Anti-CD6 antibody conjugates for the treatment of T-cell and B-cell mediated disorders and T-cell and B-cell cancer |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| TW202323282A (zh) | 2021-10-15 | 2023-06-16 | 美商賽特艾克斯生物製藥公司 | 可活化之多肽複合物 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250011422A1 (en) * | 2021-11-12 | 2025-01-09 | University Of Florida Research Foundation, Incorporated | Siglec-6 antibodies, derivative compounds and related uses |
| CN114621348B (zh) * | 2022-01-24 | 2023-09-22 | 深圳市乐土生物医药有限公司 | 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体 |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| US20250136717A1 (en) | 2022-05-16 | 2025-05-01 | Byondis B.V. | Novel masked antibodies |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| US20260049148A1 (en) | 2022-08-01 | 2026-02-19 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| EP4565260A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| AR130080A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2026513839A (ja) | 2023-04-12 | 2026-05-01 | サイトムエックス セラピューティクス，インク． | マスキングポリペプチド、活性化可能サイトカイン構成体、ならびに関連する組成物及び方法 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| AU2023464185A1 (en) * | 2023-08-28 | 2026-02-26 | Pharosgen Co., Ltd. | Anti-doppel antibody drug conjugates |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| AU9127098A (en) | 1997-09-04 | 1999-03-22 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20040048319A1 (en) | 2002-05-03 | 2004-03-11 | Mather Jennie P. | ALCAM and ALCAM modulators |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US7988964B2 (en) | 2003-12-22 | 2011-08-02 | Glaxo Group Limited | NOGO-a neutralising immunoglobulin for treatment of neurological diseases |
| US20090306347A1 (en) | 2005-08-29 | 2009-12-10 | Japan Science And Technology Agency | Antibody produced using ostrich and method for production thereof |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
| US8003762B2 (en) | 2005-11-29 | 2011-08-23 | Japan Science And Technology Agency | Monoclonal antibody to CD166 and method for production thereof |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| GB0705775D0 (en) | 2007-03-26 | 2007-05-02 | Affitech As | Product |
| JP2009055899A (ja) | 2007-08-07 | 2009-03-19 | Igaku Seibutsugaku Kenkyusho:Kk | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| CN104193824A (zh) | 2008-02-20 | 2014-12-10 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| WO2010074049A1 (ja) | 2008-12-22 | 2010-07-01 | 株式会社 未来創薬研究所 | 抗hs6st2抗体及びその用途 |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
| JP2013542958A (ja) | 2010-11-03 | 2013-11-28 | イミュノジェン・インコーポレーテッド | アンサマイトシン誘導体を含む細胞傷害性剤 |
| EP2709590A4 (en) * | 2011-05-11 | 2015-05-13 | Nanovalent Pharmaceuticals Inc | REINFORCED GROWTH INHIBITION OF OSTEOSARCOMS THROUGH CYTOTOXIC POLYMERIZED LIPOSOMAL NANOPARTICLES TO AIM AT THE ALCAM CELL SURFACE RECEPTOR |
| RU2014138474A (ru) * | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| CN110078827A (zh) * | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| JP2016509582A (ja) | 2012-12-19 | 2016-03-31 | アンプリミューン， インコーポレイテッド | 抗ヒトｂ７−ｈ４抗体およびその使用 |
| CA2896282C (en) | 2013-01-04 | 2021-07-20 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
| HK1219422A1 (zh) | 2013-02-28 | 2017-04-07 | Immunogen, Inc. | 包含细胞结合剂及细胞毒素剂的轭合物 |
| BR112015030514A2 (pt) | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| SG10202110908WA (en) | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| WO2017015227A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating cd166-expressing cancer |
| WO2017078807A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| US10562975B2 (en) | 2016-06-15 | 2020-02-18 | The Regents Of The University Of Michigan | CD6 antibody for treatment of T-cell mediated diseases or disorders |
| JP6183523B2 (ja) | 2016-09-14 | 2017-08-23 | 株式会社アンセイ | 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構 |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018071058A1 (en) | 2016-10-15 | 2018-04-19 | Baylor College Of Medicine | Platform for enhanced targeted cell delivery |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| SG11202000105QA (en) | 2017-07-14 | 2020-02-27 | Cytomx Therapeutics Inc | Anti-cd166 antibodies and uses thereof |
| BR112020004231A2 (pt) | 2017-08-30 | 2020-09-08 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| AU2019370471A1 (en) | 2018-11-02 | 2021-05-13 | Cytomx Therapeutics, Inc. | Activatable anti-CD166 antibodies and methods of use thereof |
| US20220233705A1 (en) | 2019-02-26 | 2022-07-28 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
-
2016
- 2016-05-04 SG SG10202110908WA patent/SG10202110908WA/en unknown
- 2016-05-04 AU AU2016257929A patent/AU2016257929B2/en not_active Expired - Fee Related
- 2016-05-04 CN CN202210950237.0A patent/CN115340607A/zh active Pending
- 2016-05-04 CA CA2984948A patent/CA2984948A1/en active Pending
- 2016-05-04 CN CN201680038634.3A patent/CN107849133B/zh not_active Expired - Fee Related
- 2016-05-04 PT PT167225028T patent/PT3292150T/pt unknown
- 2016-05-04 MX MX2017014136A patent/MX388350B/es unknown
- 2016-05-04 WO PCT/US2016/030785 patent/WO2016179285A1/en not_active Ceased
- 2016-05-04 EP EP20155149.6A patent/EP3708585A1/en not_active Withdrawn
- 2016-05-04 DK DK16722502.8T patent/DK3292150T3/da active
- 2016-05-04 BR BR112017023872A patent/BR112017023872A2/pt not_active IP Right Cessation
- 2016-05-04 JP JP2017557287A patent/JP7028648B2/ja not_active Expired - Fee Related
- 2016-05-04 HR HRP20200721TT patent/HRP20200721T1/hr unknown
- 2016-05-04 US US15/146,603 patent/US10745481B2/en active Active
- 2016-05-04 EA EA201792414A patent/EA201792414A1/ru unknown
- 2016-05-04 SG SG10201913767VA patent/SG10201913767VA/en unknown
- 2016-05-04 RS RS20200511A patent/RS60222B1/sr unknown
- 2016-05-04 ES ES16722502T patent/ES2796698T3/es active Active
- 2016-05-04 EP EP16722502.8A patent/EP3292150B1/en active Active
- 2016-05-04 HU HUE16722502A patent/HUE049866T2/hu unknown
- 2016-05-04 KR KR1020177034835A patent/KR20180010203A/ko not_active Abandoned
- 2016-05-04 IL IL292798A patent/IL292798A/en unknown
- 2016-05-04 PL PL16722502T patent/PL3292150T3/pl unknown
-
2017
- 2017-11-02 IL IL255414A patent/IL255414B/en unknown
- 2017-11-03 MX MX2021014735A patent/MX2021014735A/es unknown
-
2019
- 2019-12-20 US US16/723,809 patent/US11753466B2/en active Active
-
2022
- 2022-02-17 JP JP2022022910A patent/JP2022065115A/ja not_active Withdrawn
-
2023
- 2023-07-18 US US18/354,353 patent/US20240076374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520991A5 (enExample) | ||
| JP2018520092A5 (enExample) | ||
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| EP3292149B1 (en) | Activatable anti-cd71 antibodies, and methods of use thereof | |
| Carter et al. | Antibody-drug conjugates for cancer therapy | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2022522344A5 (enExample) | ||
| JP2017522871A5 (enExample) | ||
| JP2018516539A (ja) | 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 | |
| Zhang et al. | Novel development strategies and challenges for anti-Her2 antibody-drug conjugates | |
| CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
| CN105288644A (zh) | 抗体-药物缀合物 | |
| CN112020519A (zh) | 抗her2双互补位抗体-药物偶联物及使用方法 | |
| CN112175082B (zh) | 抗叶酸受体α抗体、其缀合物及其用途 | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| Bera et al. | Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability | |
| Hui et al. | An innovative site-specific anti-HER2 antibody-drug conjugate with high homogeneity and improved therapeutic index | |
| Jin et al. | An anti-EGFR× cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations | |
| JP2024545170A5 (enExample) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 | |
| JPWO2021251459A5 (enExample) | ||
| Zhong et al. | A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice |